

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BIOSTIME

Biostime International Holdings Limited

合生元國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1112)

**POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING
HELD ON 17 JANUARY 2017**

The Board is pleased to announce that, at the extraordinary general meeting (the “EGM”) of Biostime International Holdings Limited (the “Company”) held on 17 January 2017, the proposed ordinary resolution as set out in the notice of EGM dated 30 December 2016 was duly passed by way of poll. Terms used in this announcement shall have the same meanings as defined in the circular of the Company dated 30 December 2016 (the “Circular”), unless the context requires otherwise.

As at the date of the EGM, the total number of issued Shares was 631,669,964 Shares. The Target Minority Shareholders and their respective associates who are interested in 20,513,085 Shares in aggregate, representing approximately 3.25% of the total number of Shares in issue as at the date of the EGM were required to abstain, and have abstained, from voting on the proposed resolution at the EGM. Accordingly, the total number of Shares held by the Independent Shareholders who were entitled to attend and vote for or against the resolution at the EGM was 611,156,879 Shares.

Save as disclosed above, there were no restrictions on any Shareholders casting votes on the resolution proposed at the EGM. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolution at the EGM as set out in Rule 13.40 of the Listing Rules.

The Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking. The poll results of the resolution are as follows:

Ordinary Resolution	For	Against
<p>THAT the 17% Acquisition (as defined in the circular of the Company dated 30 December 2016) be and is hereby approved, confirmed and ratified; and any one director of the Company (or any two directors of the Company or any one director and the company secretary of the Company if the affixation of the common seal is necessary), be and is/are hereby authorised for and on behalf of the Company to execute all such other documents and agreements and do all such acts and things as he or they may in his or their absolute discretion consider to be necessary, desirable, appropriate or expedient to implement and/or give effect to the 17% Acquisition and all matters incidental or ancillary thereto.</p>	<p>475,275,950 (100%)</p>	<p>0 (0%)</p>

As more than 50% of the votes were cast in favour of the ordinary resolution, the ordinary resolution was duly passed by way of poll as an ordinary resolution of the Company.

By order of the Board
Biostime International Holdings Limited
Luo Fei
Chairman

Hong Kong, 17 January 2017

As at the date of this announcement, the executive Director of the Company is Mr. Luo Fei; the non-executive Directors of the Company are Dr. Zhang Wenhui, Mr. Wu Xiong, Mr. Luo Yun and Mr. Chen Fufang; and the independent non-executive Directors of the Company are Dr. Ngai Wai Fung, Mr. Tan Wee Seng and Professor Xiao Baichun.